Openvas (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Openvas, is an angiotensin II receptor blocker presented as a tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Openvas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Openvas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Openvas is an angiotensin II receptor blocker that works within the renin‑angiotensin system to lower blood pressure.

- Hypertension: helps achieve and maintain target blood pressure levels. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Heart failure: used as part of combination therapy to improve cardiac outcomes.

Adverse reactions to olmesartan medoxil are generally mild to moderate and vary among individuals.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑angry       y                                                                                                                                                                                                                                                                          - Severe hypotension - Renal impairment - Allergic reactions including Stevens‑Johnson syndrome

When using Openvas, patients should be monitored for blood pressure response and renal function.

- Monitor blood pressure: ensure target levels are achieved without excessive drop. - Assess renal function: periodic creatinine and electrolytes are recommended. - Review concomitant medications: avoid combining with potassium‑sparing diuretics without supervision. - Caution in hepatic   g   t   ewline - Use   ewline -       ewline   ewline   ewline -  ewline   ",